Summary of clinical characteristics of 16 eyes initially treated with ranibizumab for choroidal neovascularisation
| Patient no. | Diagnosis | Initial FA features of CNV | Features of exudation | Baseline vision | No. of initial ranibizumab injections | No. of injections prior to response |
| Patients initially treated with ranibizumab | ||||||
| 11 | AMD | Classic | SRF | 20/200 | 3 | 2 |
| 12 | AMD | Occult | SRF/PED | 20/60 | 5 | 1 |
| 13 | AMD | Occult | SRF/CMO/PED | 20/40 | 3 | 1 |
| 14 | AMD | Occult | CMO | 20/400 | 5 | 3 |
| 15 | AMD | Occult | SRF/PED | 20/40 | 5 | 1 |
| 16 | AMD | Occult | SRF/PED | 20/40 | 11 | 3 |
| 17 | AMD | Occult | SRF/PED | 20/60 | 5 | 1 |
| 18 | AMD | Occult | SRF/PED | 20/400 | 7 | 3 |
| 19 | AMD | Occult | SRF/CMO/PED | 20/40 | 3 | 2 |
| 20 | AMD | Occult | SRF/PED | 20/200 | 5 | 2 |
| 21 | AMD | Occult | SRF/CMO/PED | 20/60 | 3 | 2 |
| 22 | AMD | Occult | SRF | 20/100 | 4 | 1 |
| 23 | AMD | Occult | SRF/CMO/PED | 20/100 | 2 | 1 |
| 24 | AMD | Occult | SRF/CMO/PED | 20/200 | 7 | 3 |
| 25 | AMD | Occult | SRF/PED | 20/70 | 8 | 2 |
| 26 | IPCV | Occult | PED | 20/100 | 4 | 1 |
| Patient no. | Reason for switch | Vision at switch | No. of subsequent bevacizumab injections | Response after switch | No. of injections prior to response | Vision at last visit |
| Patients initially treated with ranibizumab | ||||||
| 11 | Increasing SRF | 20/400 | 2 | Yes | 1 | 20/400 |
| 12 | Increasing PED, persistent SRF | 20/50 | 3 | Yes | 2 | 20/30 |
| 13 | Increasing SRF, persistent PED | 20/25 | 3 | Yes | 1 | 20/40 |
| 14 | Persistent CMO | CF | 1 | Yes | 1 | CF |
| 15 | persistent SRF and PED | 20/40 | 2 | No | – | 20/60 |
| 16 | Persistent SRF and PED | 20/30 | 3 | Yes | 2 | 20/50 |
| 17 | Persistent SRF and PED | 20/30 | 2 | Yes | 2 | 20/30 |
| 18 | Persistent SRF | 20/200 | 2 | No | – | 20/200 |
| 19 | Persistent SRF | 20/30 | 4 | Yes | 2 | 20/30 |
| 20 | Persistent SRF and PED | 20/200 | 3 | No | – | 20/400 |
| 21 | Increasing SRF | 20/100 | 2 | Yes | 1 | 20/200 |
| 22 | Increasing SRF | 20/70 | 2 | Yes | 1 | 20/70 |
| 23 | Increasing SRF and PED | 20/40 | 6 | Yes | 1 | 20/30 |
| 24 | Persistent SRF | 20/70 | 4 | Yes | 1 | 20/80 |
| 25 | Increasing SRF and PED | 20/30 | 3 | Yes | 2 | 20/50 |
| 26 | Increasing CMO and PED | 20/50 | 2 | Yes | 1 | 20/50 |
AMD, age-related macular degeneration; CF, count fingers; CMO, cystoid macular oedema; CNV, choroidal neovascularisation; FA, flourescein angiogram; IPCV, idiopathic polypoidal choroidal vasculopathy; PED, pigment epithelial detachment; SRF, subretinal fluid.